ReviewClinical and translational allergy2018
Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management.
Review in Clinical and translational allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05080322 (A Randomized, Open-labeled, Multicenter Clinical Trial to Compare the Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Moderate-to-severe Persistent Allergic Rhinitis), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open-labeled, Multicenter Clinical Trial to Compare the Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Moderate-to-severe Persistent Allergic Rhinitis
Who cites it
15 citing papers in PubMed.
- Azelastine-Fluticasone Combination Therapy in Allergic Rhinitis: Current Evidence and Clinical Implications in Children and Adults.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review.Journal of asthma and allergy · 2024Review
- Article
- A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis.Frontiers in allergy · 2023Article
- ARIA 2019 Care Pathways for Allergic Rhinitis in the Kuwait Health Care System.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Review
- Managing Allergic Rhinitis in the Pharmacy: An ARIA Guide for Implementation in Practice.Pharmacy (Basel, Switzerland) · 2020Article
- ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye.Turkish thoracic journal · 2020Review
- Review
- Keep the cat, change the care pathway: A transformational approach to managing Fel d 1, the major cat allergen.Allergy · 2019Article
- Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2).Journal of thoracic disease · 2019Review
- Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1).Journal of thoracic disease · 2019Article
- Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement.Clinical and translational allergy · 2019Review
- ARIA guideline 2019: treatment of allergic rhinitis in the German health system.Allergologie select · 2019Article
- Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases.Clinical and translational allergy · 2019Review
- Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases.Clinical and translational allergy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis article summarizes a EUFOREA symposium, presented during the European Rhinology Research Forum in Brussels (9-10 November 2017; https://www.rhinologyresearch.eu/) which focused on novel pathways and therapeutic approaches in allergic rhinitis (AR). MAIN BODY: AR remains under-diagnosed, under-estimated and under-treated. A key component in understanding the AR landscape has been the realization of a significant mismatch between how physicians instruct AR patients to manage their disease and what AR patients actually do in real life. Data from the
conclusionWith the most rapid onset of action and onset of clinically-relevant effect of any AR medication currently available, and proven efficacy in the treatment of NHR, MP-AzeFlu is an AR treatment which provides what patients want, and fits how patients manage their AR in real life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.